[go: up one dir, main page]

DK1968632T3 - Forbedret influenzavaccine - Google Patents

Forbedret influenzavaccine

Info

Publication number
DK1968632T3
DK1968632T3 DK06821622.5T DK06821622T DK1968632T3 DK 1968632 T3 DK1968632 T3 DK 1968632T3 DK 06821622 T DK06821622 T DK 06821622T DK 1968632 T3 DK1968632 T3 DK 1968632T3
Authority
DK
Denmark
Prior art keywords
epitope
influenza
influenza vaccine
present
improved influenza
Prior art date
Application number
DK06821622.5T
Other languages
English (en)
Inventor
Ruth Arnon
Tamar Ben-Yedidia
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK1968632T3 publication Critical patent/DK1968632T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK06821622.5T 2005-12-06 2006-12-06 Forbedret influenzavaccine DK1968632T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74253005P 2005-12-06 2005-12-06
US74257405P 2005-12-06 2005-12-06
PCT/IL2006/001403 WO2007066334A1 (en) 2005-12-06 2006-12-06 Improved influenza vaccine

Publications (1)

Publication Number Publication Date
DK1968632T3 true DK1968632T3 (da) 2012-07-16

Family

ID=37776792

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06821622.5T DK1968632T3 (da) 2005-12-06 2006-12-06 Forbedret influenzavaccine

Country Status (9)

Country Link
US (1) US7914797B2 (da)
EP (1) EP1968632B1 (da)
AT (1) ATE552846T1 (da)
AU (1) AU2006322907B2 (da)
CA (1) CA2632483C (da)
DK (1) DK1968632T3 (da)
ES (1) ES2385842T3 (da)
PT (1) PT1968632E (da)
WO (1) WO2007066334A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027314A1 (en) * 2006-01-27 2011-02-03 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Influenza Vaccines Containing Hemagglutinin and Matrix Proteins
EP1991264B1 (en) 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
MX2010001284A (es) 2007-08-02 2010-08-31 Biondvax Pharmaceuticals Ltd Vacunas contra la influenza con multiepitope multimerico.
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
WO2009029686A1 (en) 2007-08-27 2009-03-05 Longhorn Vaccines & Diagnostics Llc Immunogenic compositions and methods
US20110027315A1 (en) * 2007-09-07 2011-02-03 Allen Harmsen Protein cages and their uses
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
PL222497B1 (pl) 2009-06-26 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
BR112012020839A2 (pt) * 2010-02-18 2017-11-21 Sinai School Medicine vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
US9555093B2 (en) 2010-04-30 2017-01-31 Temasek Life Sciences Laboratory Limited Universal vaccine against H5N1 lineages
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
BR112014006694A2 (pt) 2011-09-20 2020-11-17 Mount Sinai School Of Medicine vacinas contra o vírus influenza e usos dessas
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10286062B2 (en) 2013-07-09 2019-05-14 Texas Tech University System Universal influenza vaccine
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3103474A1 (en) * 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
US10370416B2 (en) 2016-03-01 2019-08-06 Texas Tech University System Dual purpose universal influenza vaccine confers protective immunity against anthrax
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
CN111148528A (zh) 2016-12-28 2020-05-12 英福瓦克思公司 流感疫苗
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN117430664B (zh) * 2023-10-24 2024-04-09 暨南大学附属第六医院(东莞市东部中心医院) 一种甲型流感病毒t细胞抗原表位肽及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
IL109664A0 (en) 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
EP0941315B1 (en) 1996-11-26 2006-03-01 Stressgen Biotechnologies Corporation Fusion proteins containing stress proteins for inducing immune responses
ES2255181T3 (es) 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
CN1196788C (zh) * 2000-06-23 2005-04-13 惠氏控股有限公司 野生型和嵌合流感病毒样颗粒(vlp)的装配
AU2004220549B2 (en) 2003-03-07 2007-07-05 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Influenza virus vaccine

Also Published As

Publication number Publication date
US20090304730A1 (en) 2009-12-10
WO2007066334A1 (en) 2007-06-14
AU2006322907A1 (en) 2007-06-14
CA2632483C (en) 2014-11-25
EP1968632B1 (en) 2012-04-11
EP1968632A1 (en) 2008-09-17
PT1968632E (pt) 2012-07-16
AU2006322907B2 (en) 2012-08-02
CA2632483A1 (en) 2007-06-14
ATE552846T1 (de) 2012-04-15
US7914797B2 (en) 2011-03-29
WO2007066334A9 (en) 2009-09-11
ES2385842T3 (es) 2012-08-01

Similar Documents

Publication Publication Date Title
DK1968632T3 (da) Forbedret influenzavaccine
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
WO2007011904A3 (en) Recombinant flu vaccines
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
EA201171128A1 (ru) Оптимизированный ранний/поздний промотор в сочетании с повторной вакцинацией способствует ответу цитотоксических т- клеток против антигенов рекомбинантных вакцин, основанных на вирусе с дефицитом по репликации
NO20090194L (no) Rekombinant viral vaksine
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
MX2015013235A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
GEP20135924B (en) Chimeric viruses presenting non-native surface proteins and usage thereof
MXPA05009580A (es) Vacuna contra el virus de la influenza.
DK2707393T3 (da) Fusionsproteiner og kombinationsvacciner omfattende haemoph-ilus influenzae-protein e og pilin a
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
EA201390806A1 (ru) Конструкция пептидного каркаса
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
PE20121685A1 (es) Antigeno ndv recombinante y usos del mismo
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
WO2006115843A3 (en) Nipah virus vaccines
NZ627888A (en) Materials and methods for respiratory disease control in canines
WO2016116905A9 (en) Cmv antigens and uses thereof
EA201690115A1 (ru) Комбинированные иммуногенные композиции
NZ602380A (en) Peptides for vaccine against birch allergy